This Article  • Full text  • PDF  • Author in the Room Audio  • Correction  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (181)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Oncology  • Breast Cancer  • Alert me on articles by topic

The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Victor G. Vogel, MD, MHS; Joseph P. Costantino, DrPH; D. Lawrence Wickerham, MD; Walter M. Cronin, MPH; Reena S. Cecchini, MS; James N. Atkins, MD; Therese B. Bevers, MD; Louis Fehrenbacher, MD; Eduardo R. Pajon Jr, MD; James L. Wade III, MD; André Robidoux, MD; Richard G. Margolese, MD, CM; Joan James, PA-C; Scott M. Lippman, MD; Carolyn D. Runowicz, MD; Patricia A. Ganz, MD; Steven E. Reis, MD; Worta McCaskill-Stevens, MD; Leslie G. Ford, MD; V. Craig Jordan, PhD, DSc; Norman Wolmark, MD; for the National Surgical Adjuvant Breast and Bowel Project (NSABP)

JAMA. 2006;295:2727-2741. Published online June 5, 2006 (doi:10.1001/jama.295.23.joc60074).

Context  Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.

Objective  To compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes.

Design, Setting, and Patients  The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial, a prospective, double-blind, randomized clinical trial conducted beginning July 1, 1999, in nearly 200 clinical centers throughout North America, with final analysis initiated after at least 327 incident invasive breast cancers were diagnosed. Patients were 19 747 postmenopausal women of mean age 58.5 years with increased 5-year breast cancer risk (mean risk, 4.03% [SD, 2.17%]). Data reported are based on a cutoff date of December 31, 2005.

Intervention  Oral tamoxifen (20 mg/d) or raloxifene (60 mg/d) over 5 years.

Main Outcome Measures  Incidence of invasive breast cancer, uterine cancer, noninvasive breast cancer, bone fractures, thromboembolic events.

Results  There were 163 cases of invasive breast cancer in women assigned to tamoxifen and 168 in those assigned to raloxifene (incidence, 4.30 per 1000 vs 4.41 per 1000; risk ratio [RR], 1.02; 95% confidence interval [CI], 0.82-1.28). There were fewer cases of noninvasive breast cancer in the tamoxifen group (57 cases) than in the raloxifene group (80 cases) (incidence, 1.51 vs 2.11 per 1000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 with raloxifene (RR, 0.62; 95% CI, 0.35-1.08). No differences were found for other invasive cancer sites, for ischemic heart disease events, or for stroke. Thromboembolic events occurred less often in the raloxifene group (RR, 0.70; 95% CI, 0.54-0.91). The number of osteoporotic fractures in the groups was similar. There were fewer cataracts (RR, 0.79; 95% CI, 0.68-0.92) and cataract surgeries (RR, 0.82; 95% CI, 0.68-0.99) in the women taking raloxifene. There was no difference in the total number of deaths (101 vs 96 for tamoxifen vs raloxifene) or in causes of death.

Conclusions  Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts but a nonstatistically significant higher risk of noninvasive breast cancer. The risk of other cancers, fractures, ischemic heart disease, and stroke is similar for both drugs.

Trial Registration  clinicaltrials.gov Identifier: NCT00003906

Author Affiliations: Magee-Womens Hospital, University of Pittsburgh School of Medicine (Dr Vogel) and Graduate School of Public Health (Dr Costantino), University of Pittsburgh, Pittsburgh, Pa; National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh (Drs Costantino, Wickerham, and Wolmark and Mr Cronin and Ms Cecchini); Allegheny General Hospital, Pittsburgh (Drs Wickerham and Wolmark); Southeast Cancer Control Consortium, Winston-Salem, NC (Dr Atkins); University of Texas M. D. Anderson Cancer Center, Houston (Drs Bevers and Lippman); Kaiser Permanente Northern California, Vallejo (Dr Fehrenbacher); Colorado CCOP, Denver Veterans Medical Center, Denver (Dr Pajon); Central Illinois CCOP, Decatur (Dr Wade); Centre hospitalier de l’Université de Montréal, Montréal, Quebec (Dr Robidoux); Jewish General Hospital, McGill University, Montréal (Dr Margolese); Fox Chase Cancer Center, Philadelphia, Pa (Ms James and Dr Jordan); University of Connecticut Health Center, Neag Comprehensive Cancer Center, Farmington (Dr Runowicz); UCLA Schools of Public Health and Medicine and Jonsson Comprehensive Cancer Center, Los Angeles, Calif (Dr Ganz); University of Pittsburgh, Pittsburgh (Dr Reis); and National Cancer Institute/National Institutes of Health, Bethesda, Md (Drs McCaskill-Stevens and Ford).

RELATED LETTERS

Raloxifene vs Tamoxifen
Steven R. Goldstein
JAMA. 2007;297(3):263-264.
EXTRACT | FULL TEXT  

Raloxifene vs Tamoxifen—Reply
William J. Gradishar and David Cella
JAMA. 2007;297(3):264.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer
William J. Gradishar and David Cella
JAMA. 2006;295(23):2784-2786.
EXTRACT | FULL TEXT  

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Stephanie R. Land, D. Lawrence Wickerham, Joseph P. Costantino, Marcie W. Ritter, Victor G. Vogel, Myoungkeun Lee, Eduardo R. Pajon, James L. Wade, III, Shaker Dakhil, James B. Lockhart, Jr, Norman Wolmark, and Patricia A. Ganz
JAMA. 2006;295(23):2742-2751.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
DeMichele et al.
JCO 2008;26:4151-4159.
ABSTRACT | FULL TEXT  

Management of breast cancer--Part I
Turner and Jones
BMJ 2008;337:a421-a421.
FULL TEXT  

Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer
Eng-Wong et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1696-1701.
ABSTRACT | FULL TEXT  

Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention
Grabowski and Moe
Cancer Prevention Research 2008;1:84-90.
ABSTRACT | FULL TEXT  

The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?
Jordan
JCO 2008;26:3073-3082.
ABSTRACT | FULL TEXT  

Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
Grady et al.
JNCI J Natl Cancer Inst 2008;100:854-861.
ABSTRACT | FULL TEXT  

The Rise of Raloxifene and the Fall of Invasive Breast Cancer
Jordan
JNCI J Natl Cancer Inst 2008;100:831-833.
FULL TEXT  

Review of Comparative Effectiveness of Treatments to Prevent Fractures
Stock et al.
ANN INTERN MED 2008;148:885-885.
FULL TEXT  

Review of Comparative Effectiveness of Treatments to Prevent Fractures
MacLean et al.
ANN INTERN MED 2008;148:887-887.
FULL TEXT  

Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT  

Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment
Pories et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1034-1042.
ABSTRACT | FULL TEXT  

Estrogen Receptor Regulation of Carbonic Anhydrase XII through a Distal Enhancer in Breast Cancer
Barnett et al.
Cancer Res. 2008;68:3505-3515.
ABSTRACT | FULL TEXT  

Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time
Lin and Winer
JCO 2008;26:1919-1921.
FULL TEXT  

Menopausal symptoms and adjuvant therapy-associated adverse events
Hadji
Endocr Relat Cancer 2008;15:73-90.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT  

Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT | FULL TEXT  

Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Levy et al.
Mol. Endocrinol. 2008;22:287-303.
ABSTRACT | FULL TEXT  

Publication of Clinical Trials in JAMA: Information for Authors
Fontanarosa and DeAngelis
JAMA 2008;299:95-96.
FULL TEXT  

The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
Fatouros et al.
Ann. Surg. Oncol. 2008;15:21-33.
ABSTRACT | FULL TEXT  

Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan and O'Malley
JCO 2007;25:5815-5824.
ABSTRACT | FULL TEXT  

Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women
Gail et al.
JNCI J Natl Cancer Inst 2007;99:1782-1792.
ABSTRACT | FULL TEXT  

Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status
Chlebowski et al.
JNCI J Natl Cancer Inst 2007;99:1695-1705.
ABSTRACT | FULL TEXT  

Compliance With Patient-Reported Outcomes in Multicenter Clinical Trials: Methodologic and Practical Approaches
Land et al.
JCO 2007;25:5113-5120.
ABSTRACT | FULL TEXT  

Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward
Lipscomb et al.
JCO 2007;25:5133-5140.
ABSTRACT | FULL TEXT  

Proliferative Changes in Chemoprevention Trials: Learning From Secondary Endpoints
Szabo
JNCI J Natl Cancer Inst 2007;99:1565-1567.
FULL TEXT  

Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer
Deshmane et al.
JCO 2007;25:4967-4973.
ABSTRACT | FULL TEXT  

Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point
Jordan
Cancer Epidemiol. Biomarkers Prev. 2007;16:2207-2209.
FULL TEXT  

Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A Tale of Two Choices Counterpoint
Fabian
Cancer Epidemiol. Biomarkers Prev. 2007;16:2210-2212.
FULL TEXT  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT | FULL TEXT  

The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor Negative Tumors in MMTV-erbB2 Mice
Li et al.
Clin. Cancer Res. 2007;13:6224-6231.
ABSTRACT | FULL TEXT  

Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research
Hoque et al.
Cancer Res. 2007;67:8989-8993.
ABSTRACT | FULL TEXT  

Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users
Decensi et al.
JCO 2007;25:4201-4209.
ABSTRACT | FULL TEXT  

Ontology, Oncology, and Preventive Economies: Developing Drugs for Cancer Prevention
Vogel
Clin. Cancer Res. 2007;13:5227-5228.
FULL TEXT  

Follow-up of Patients with Early Breast Cancer
Sakemi et al.
NEJM 2007;357:1052-1053.
FULL TEXT  

Can Statins Pass the Aspirin Litmus Test in Cancer?
Kauh and Khuri
JCO 2007;25:3395-3396.
FULL TEXT  

Chemoprevention Clinical Trials: It Is Time to Turn Success into Progress
Brown
Cancer Epidemiol. Biomarkers Prev. 2007;16:1531-1532.
FULL TEXT  

A Pilot and Feasibility Study on the Effects of Naturopathic Botanical and Dietary Interventions on Sex Steroid Hormone Metabolism in Premenopausal Women
Greenlee et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1601-1609.
ABSTRACT | FULL TEXT  

Impact of Randomized Clinical Trial Results in the National Comprehensive Cancer Network on the Use of Tamoxifen After Breast Surgery for Ductal Carcinoma in Situ
Yen et al.
JCO 2007;25:3251-3258.
ABSTRACT | FULL TEXT  

Management of an Inherited Predisposition to Breast Cancer
Robson and Offit
NEJM 2007;357:154-162.
FULL TEXT  

Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
Kauff and Barakat
JCO 2007;25:2921-2927.
ABSTRACT | FULL TEXT  

Follow-up of Patients with Early Breast Cancer
Hayes
NEJM 2007;356:2505-2513.
FULL TEXT  

Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model
Santen et al.
Endocr Relat Cancer 2007;14:169-187.
ABSTRACT | FULL TEXT  

Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
Veronesi et al.
JNCI J Natl Cancer Inst 2007;99:727-737.
ABSTRACT | FULL TEXT  

Atypia in Random Periareolar Fine-Needle Aspiration Affects the Decision of Women at High Risk to Take Tamoxifen for Breast Cancer Chemoprevention
Goldenberg et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1032-1034.
ABSTRACT | FULL TEXT  

Cancer Chemoprevention: How Do We Know What Works?
Neugut et al.
JCO 2007;25:1461-1462.
FULL TEXT  

U.S. Food and Drug Administration Analysis of Strokes Associated With Raloxifene
Wyeth et al.
Obstet Gynecol 2007;109:999-999.
FULL TEXT  

Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen-Induced Murine Lung Tumors
Granville et al.
Clin. Cancer Res. 2007;13:2281-2289.
ABSTRACT | FULL TEXT  

SERMs: Meeting the Promise of Multifunctional Medicines
Jordan
JNCI J Natl Cancer Inst 2007;99:350-356.
ABSTRACT | FULL TEXT  

Update in Osteoporosis and Metabolic Bone Disorders
Shoback
J. Clin. Endocrinol. Metab. 2007;92:747-753.
ABSTRACT | FULL TEXT  

Long-term Recreational Physical Activity and Risk of Invasive and In Situ Breast Cancer: The California Teachers Study
Dallal et al.
Arch Intern Med 2007;167:408-415.
ABSTRACT | FULL TEXT  

Tamoxifen: An Enduring Star
Veronesi et al.
JNCI J Natl Cancer Inst 2007;99:258-260.
FULL TEXT  

Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial
Cuzick et al.
JNCI J Natl Cancer Inst 2007;99:272-282.
ABSTRACT | FULL TEXT  

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial
Powles et al.
JNCI J Natl Cancer Inst 2007;99:283-290.
ABSTRACT | FULL TEXT  

The Fight Against Tamoxifen Resistance in Breast Cancer Therapy: A New Target in the Battle?
Nichols
Mol. Interv. 2007;7:13-16.
ABSTRACT | FULL TEXT  

Raloxifene vs Tamoxifen
Goldstein
JAMA 2007;297:263-264.
FULL TEXT  

Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology
Ozols et al.
JCO 2007;25:146-162.
ABSTRACT | FULL TEXT  

Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
Chatterton et al.
J Endocrinol 2006;191:599-604.
ABSTRACT | FULL TEXT  

Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk
Stearns
Evid. Based Med. 2006;11:177-177.
FULL TEXT  

Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk
Thacker
Evid. Based Med. 2006;11:178-178.
FULL TEXT  

Prescription of tamoxifen for breast cancer prevention by primary care physicians.
Armstrong et al.
Arch Intern Med 2006;166:2260-2265.
ABSTRACT | FULL TEXT  

Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies.
Meadows et al.
Med Decis Making 2006;26:633-635.
 

Skeletal complications of breast cancer therapies.
Hirbe et al.
Clin. Cancer Res. 2006;12:6309s-6314s.
ABSTRACT | FULL TEXT  

Long-term raloxifene in a woman at high risk for breast cancer.
Bean et al.
NEJM 2006;355:1620-1622.
FULL TEXT  

Effect of Raloxifene on Bone Mineral Density in Premenopausal Women at Increased Risk of Breast Cancer
Eng-Wong et al.
J. Clin. Endocrinol. Metab. 2006;91:3941-3946.
ABSTRACT | FULL TEXT  

The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor-Negative Model of Breast Cancer.
Liby et al.
Clin. Cancer Res. 2006;12:5902-5909.
ABSTRACT | FULL TEXT  

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk
Lippman et al.
Clin. Cancer Res. 2006;12:5242-5247.
ABSTRACT | FULL TEXT  

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor et al.
NEJM 2006;355:125-137.
ABSTRACT | FULL TEXT  

Raloxifene vs. Tamoxifen: Breast Cancer and Other Outcomes in the STAR Trial
JWatch Women's Health 2006;2006:2-2.
FULL TEXT  

Raloxifene vs. Tamoxifen in Reducing Risk for Invasive Breast Cancer
JWatch General 2006;2006:1-1.
FULL TEXT  

What's new in the other general journals.
Tonks
BMJ 2006;333:37-38.
FULL TEXT  

Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer
Gradishar and Cella
JAMA 2006;295:2784-2786.
FULL TEXT  

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Land et al.
JAMA 2006;295:2742-2751.
ABSTRACT | FULL TEXT